ADMA Biologics

Aging Population And Plasma Supply Will Drive Industry Expansion

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

29 Apr 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$35.00

49.6% undervalued

15 Aug

US$17.63

-3.2%

7.6%

Author's Valuation

US$35.0

49.6% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25

AnalystHighTarget Fair Value

US$35.0

49.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

20.60%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$366.56m

Earnings '28

29.76x

PE Ratio '28

US$10.91b

Market Cap '28

US$10.91b

Market Cap '28

256.08m

No. shares '28

US$42.59

Share Price '28

US$42.59 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$34.99

Fair Value '25